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Abstract 
 
BACKGROUND:  
 
Breast cancer is the most common type of cancer in women despite advances in research 
and detection methods.  Approximately 25 to 30 percent of newly diagnosed cases of breast 
cancer will overexpress HER2, human epidermal growth factor receptor 2, and are at a greater 
risk for disease progression and poorer clinical outcomes.  The traditional treatment is associated 
with irreversible cardiac dysfunction.  An alternative treatment involving lapatinib plus 
capecitabine has been reported in some randomized controlled clinical trials comparing treatment 
outcomes.  To quantify the effectiveness of lapatinib plus capecitabine combination therapy 
versus capecitabine monotherapy in treating metastatic breast cancer, a systemic review seems 
necessary.  In this thesis, meta-analysis was performed to synthesize the ratio of the odds of 
patient death or disease progression for breast cancer patients who are treated with a combination 
therapy to the odds for patients who are treated with monotherapy. 
METHODS: 
 
Several randomized clinical trials are identified comparing combination therapy lapatinib 
plus capecitabine versus capecitabine monotherapy in women with metastatic HER2 positive 
breast cancer that had disease progression after treatment with regimens that included an 
anthracycline, a taxane, and trastuzumab.  Patients in the treatment arm received lapatinib dosed 
at 1,500 mg per day continuously plus capecitabine 2,000 mg per square meter of body surface 
area on days 1 through 14 of a 21 day cycle.  Patients in the control arm received capecitabine at 
a dose of 2,500 mg per square meter of body surface area on days 1 through 14 of a 21 day cycle.  
Mantel–Haenszel fixed effect meta-analysis was used to combine the data to evaluate frequency 
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of the events between combination therapy and monotherapy treatments in a heavily pre-treated 
metastatic breast cancer population. 
CONCLUSION: 
 
Three eligible clinical trials were identified, reporting outcomes on 1,131 women.  
Mantel–Haenszel fixed effect analysis showed the event occurred 26.7 percent less frequently for 
women treated with combination lapatinib plus capecitabine (odds ratio [OR], 0.733; 95 percent 
confidence interval [CI], 0.565 to 0.952) than patients treated with capecitabine monotherapy.  
The use of lapatinib plus capecitabine should be evaluated in clinical trial for newly diagnosed 
HER2 positive patients or older patients who might otherwise be exposed to potential serious 
adverse side effects as a result of the current first line treatment or patients that have a pre-
existing heart condition. 
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Chapter I: INTRODUCTION 
Breast cancer is the most common type of cancer in women despite advances in research and 
detection methods.  Breast cancer is the second most common cancer in the world, and by far the 
most frequent cancer among women with an estimated 1.67 million newly diagnosed cases in 
2012 resulting in over 400,000 deaths worldwide (World Health Organization, 2015).  Public 
health data suggests that the global burden of breast cancer in women, measured by incidence 
and mortality, is substantial and on the rise.  There is an increasing number of global health 
initiatives to address breast cancer including efforts by Susan G. Komen for the Cure ©, the 
Breast Health Global Initiative, the U.S. Centers for Disease Control and Prevention, the 
American Cancer Society, the National Cancer Institute, and ongoing work by leading oncology 
societies in different parts of the world. 
In the United States an estimated 234,190 (2,350 men and 231,840 women) will be 
diagnosed with breast cancer; and, an estimated 40,730 (440 men and 40,290 women) will die 
from breast cancer in 2014 (Jemal, Siegel, Xu &Ward 2014).  Approximately 25 to 30 percent of 
newly diagnosed cases of breast cancer will overexpress HER2, human epidermal growth factor 
receptor 2, and are at greater risk for disease progression and poorer clinical outcomes (Geyer et 
al. 2008; Cameron et al. 2010).  The HER proteins are transmembrane receptors which regulate: 
cell growth, survival, adhesion, migration, and differentiation (Hudis, 2007).  In some breast 
cancers, HER2 is over-expressed and causes breast cells to reproduce uncontrollably.   
In 1998, the FDA approved: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab as 
first-line treatment for women with HER2 positive breast cancer.  This first line treatment for 
naïve HER2 positive breast cancer showed biological activity in controlling breast cancer 
growth.  The chemotherapy regimen is abbreviated as ACTH followed by H maintenance for 1 
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year.  The A refers to Adriamycin® ( doxorubicin, Ben Venue Laboratories, Inc., Bedford, OH), 
the C refers to Cytoxan® (cyclophosphamide, Bristol-Myers Squibb, New York, NY), the T 
refers to Taxol®  (paclitaxel, Bristol-Myers Squibb, New York, NY), and H refers to Herceptin® 
(trastuzumab, Genetech, San Francisco, CA).   
Unfortunately, this treatment regime is associated with irreversible cardiac dysfunction 
which can develop into congestive heart failure (CHF) that can manifest at any time during 
treatment and may also occur years and possibly decades after treatment has completed (Bowles 
et al., 2012).  A retrospective study of 12,000 women who received breast cancer treatment 
between 1999 and 2007 reported that patients who received chemotherapy agents such as: 
anthracyclines and trastuzumab have a 20 percent increased risk of developing congestive heart 
failure within five years after finishing chemotherapy (Bowles et al. 2012; Pinder, Duan, 
Goodwin, Hortobagyi & Giordano, 2007).  Nevertheless, the side effect profiles of the 
chemotherapy agents, especially when used in combination, must be factored into treatment 
decision to maximize quality of life and prolonging patient survival.  This is of particular 
importance to breast cancer survivors because the development of congestive heart failure is 
more pronounced in older patients and females.  
Patients that have disease progression or reoccurrence following treatment with: 
anthracycline, a taxane, and trastuzumab have limited treatment options available due to a lack of 
other HER2 antagonists.  The data is pooled from HER2 positve metastatic or advanced breast 
cancer clinical trials of combination therapy of lapatinib plus capecitabine versus capecitabine 
monotherapy.  In this thesis, meta-analysis was performed to synthesize the ratio of the odds of 
patient death or disease progression for breast cancer patients who are treated with a combination 
therapy to the odds for patients who are treated with monotherapy. 
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Chapter II: LITERTURE REVIEW 
 
The scientific advancement in treatment of breast cancer is as varied as the history of breast 
cancer.  In understanding the significant side effects that chemotherapy drug(s) pose to the 
patient, one is required to comprehend the significance of the treatment options available to 
women who have been diagnosed with breast cancer.   
History of Breast Cancer 
 
The history of breast cancer is unique.  This type of cancer can be seen by the naked eye as a 
result of the transformation of the breast structure.  The treatment option for women diagnosed 
with breast cancer begins with a journey through the history of medicine.   
The ancient Greek physician Hippocrates, the founder of Western Medicine, in 460 B.C. 
reported the earliest documented case of breast cancer.  He noted that women developed hard 
lumps in their breast tissue which would swell and turn black.  Hippocrates theorized that the 
women suffered from a humoral disease, a systemic imbalance of the humors (blood, phlegm, 
yellow and black bile) resulting in illness and death (Random History, 2008).   
A major advancement of medicine occurred in the late 1700s when Dr. Henri Le Dran 
proposed that breast cancer was a single-site disease which surgery alone could cure (Random 
History, 2008).  Since the patient was not anesthetized, the need for quickness, and not surgical 
skill, left women with horrible disfigurements of the chest wall.  The women endured chronic 
pain and swelling in the arms from impaired lymphatic circulation (Random History, 2008).  
The introduction of anesthesia in the mid-1800s allowed surgeons to have more time to 
skillfully remove the breast tissue.  The radical mastectomy was introduced by Dr. William 
Halstead.  A radical mastectomy, more commonly called, a bilateral radical mastectomy in 
modern terms, is the complete removal of: both breasts, both pectoral chest muscles (major and 
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minor) and the axillary lymph nodes in a single surgical procedure (Donegan & Spratt, 2002).  
The radical mastectomy was gold standard in the treatment of breast cancer for 100 years until 
the development of chemotherapeutic agents in the mid-1900s (Random History, 2008).  
Unfortunately, women still endured chronic pain and swelling following the surgery. 
In 1955, Dr. George Crile argued that breast cancer was a systemic disease and argued 
against the radical mastectomy indicating the procedure as too invasive and unnecessary.  He 
proposed a more conservative mastectomy that only removed the breast cancer and some of the 
surrounding tissue but not the entire breast.  The hormone estrogen receptor was also identified 
during this time period and became a useful tool in classifying breast cancer.   
The introduction of radiotherapy, hormone therapy, and chemotherapy in the 1970s improved 
the survival chance of some women; however, a large majority of women still died from the 
disease (Donegan & Spratt, 2002).  In 1980s, researchers identified a receptor that was over- 
expressed in some breast cancer; the HER2 receptor.  This was recognized as a cancer 
distinguisher, useful in staging and categorizing various breast cancers.  The correlation between 
the estrogen receptor and HER2 status was not fully understood until the development of 
chemotherapy drugs and hormone antagonists which could block or inhibit the specific receptors.  
The current knowledge of HER2 positive and estrogen receptor status is what medical 
oncologists and researchers are using to develop new chemotherapy treatments in the search of a 
cure for breast cancer. 
A journey through the history of breast cancer has shown that as medical knowledge has 
increased; the treatments and surgical options available to women have advanced; the survival 
outcome of this deadly disease has improved.  The national awareness which breast cancer has 
received in the past two decades has increased funding, both privately and nationally, in hopes of 
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finding a cure.  The efforts by organizations like Susan G. Komen for the Cure © and 
highlighting October as National Breast Cancer Awareness Month has taken breast cancer out of 
the closet and into the living rooms of the American household.  The treatment options available 
for women in the twenty-first century are a vast improvement than what was offered in 
Hippocrates’ time.   
Chemotherapeutic Agents 
 
A discussion of the drugs utilized and the significant side effects is needed to comprehend 
the potential risks women accept when starting chemotherapy treatment.  The following drugs 
are commonly used in the first line treatment for metastatic breast cancer  Adriamycin® 
(doxorubicin, Ben Venue Laboratories, Inc., Bedford, OH), Cytoxan® (cyclophosphamide, 
Bristol-Myers Squibb, New York, NY), Taxol®  (paclitaxel, Bristol-Myers Squibb, New York, 
NY), Herceptin®  (trastuzumab, Genetech, San Francisco, CA), lapatinib (Tykerb® or Tyverb®, 
GlaxoSmithKline, Research Triangle Park, NC), and capecitabine (Xeloda ®, Roche, San 
Francisco, CA).  
Doxorubicin mode of action  is to impede the DNA topoisomerase which repairs damaged 
DNA and generating free radical that cause damage to the cell membrane, DNA, and proteins.  
Doxorubicin is associated with irreversible cardiac dysfunction.  Cardiac dysfunction is defined 
as any alteration in the normal function of the heart.  Cardiac dysfunction can occur at any dose 
of doxorubicin which can manifest as the potentially fatal congestive heart failure (CHF) 
occurring at any time during therapy, even months to years after termination of treatment 
(Adriamycin [package insert]. Bedford, OH: Ben Venue Laboratories, Inc.; 2006).   
Cyclophosphamide and paclitaxel are two chemotherapy agents are not associated with life 
threating side effects, but they are still cytotoxic agents.  Cyclophosphamide crosslinks DNA 
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strands by the addition of an alkyl group of guanine which inhibits DNA replication leading to 
cellular apoptosis.  Paclitaxel stabilizes the microtubules preventing disassembly during cell 
division stopping the cell life cycle.  Cyclophosphamide and paclitaxel are associated with 
myelosuppression (also known as bone marrow suppression).  Myelosuppression is a condition 
in which bone marrow activity is decreased resulting in fewer red blood cells, white blood cells, 
and platelets.  Prolonged myelosuppression can result in bacterial, fungal, or viral infections that 
can delay treatment.  Myelosuppression is dose related and normally resolves upon a dose 
reduction or termination of treatment. 
Trastuzumab is a human monoclonal antibody which targets the extracellular domain of the 
HER2 receptor that inhibits the phosphorylation of key proteins needed to regulate the cell life 
cycle.  The breast cancer cells that have been treated with trastuzumab induce immune cells to 
kill the cancer cell.  The antibody-dependent cell cytotoxicity is an important mechanism in 
killing the cancer cells (Hudis, 2007).  Trastuzumab was a pivotal advancement in the treatment 
of breast cancer.  In 2001, research showed that trastuzumab can increase the incidence of 
cardiac dysfunction when used in combination with doxorubicin, cyclophosphamide, and 
paclitaxel which was an unexpected complication based on preclinical trials (Slamon et al., 
2001).  Unfortunately, trastuzumab is associated with a natural and acquired resistance which 
can develop during the course of treatment and recurrences following trastuzumab therapy still 
occur.   
Lapatinib is the first orally available dual inhibitor of both the HER2 and EGFR (epidermal 
growth factor receptor) tyrosine kinases; a dual inhibitor may benefit more patients due to the 
role of EGFR and HER2 in the progression of various cancers including, but not limited to, 
breast, colon, head and neck, and bladder cancers (Kopper, 2008).  Lapatinib blocks the 
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intracellular domain of the HER2 and EGFR receptors which prevents phosphorylation of key 
proteins that regulate the cell life cycle, resulting in mechanisms that lead to cell death.  The role 
of the EGFR and HER2 in cellular proliferation, differentiation and survival provides strong 
rationale for utilizing chemotherapy agents, such as lapatinib, that block EFGR or HER2 
signaling pathways in tumors that overexpress EFGR or HER2 (Tevaarwerk & Kolesar, 2009).  
Lapatinib is associated with hepatotoxicity and left ventricle ejection fraction (LVEF) decline 
that may be severe and result in death (Tykerb® or Tyverb® [package insert], GlaxoSmithKline, 
Research Triangle Park, NC, 2015). 
Capecitabine is an orally available chemotherapeutic agent used in the treatment of 
metastatic breast and colorectal cancers.  Capecitabine is a prodrug that is enzymatically 
converted into 5-fluorouracil (5FU) by thymidine phosphorlase which is present at a higher 
concentration within tumor cells (Walko & Lindley, 2005).  The higher concentration of 5FU 
inhibits deoxyribonucleic acid (DNA) synthesis in cancer cells thus sparing healthy tissue.  The 
primary side effect of capecitabine is hand-foot syndrome.  Hand-foot syndrome is a thickening 
of the skin on the hand and feet that cause severe pain, numbness and/or peeling of the skin.  
This reversible side effect is dose dependent and will resolve upon a dose reduction of 
capecitabine or discontinuation of treatment.   
Clinical Trials 
 
The women who have developed irreversible cardiac dysfunction or have progressive disease 
after trastuzumab therapy had few treatment options available until the FDA approved lapatinib 
in 2007.  The FDA approved lapatinib in combination with capecitabine for the treatment of 
HER2 positive breast cancer for those patients who had disease progression while on or after 
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trastuzumab therapy.  The treatment regimen of lapatinib and capecitabine shows clinical benefit 
in the treatment of locally advanced (Stage III) or metastatic (Stage IV) breast cancer.    
The combination treatment of lapatinib and capecitabine showed a 51% increase in the time 
to tumor progression (TTP), as elaborated by Geyer et al (2006) in the New England Journal of 
Medicine.  The research also demonstrated no increase of serious side effects or decrease in the 
left ventricle ejection fraction (LVEF).  However, this study was biased on the population 
selection; the eligibility criteria required that the women have normal cardiac function before 
starting investigational treatment. 
The EGF100151 study by Cameron et al. (2010) showed a need for further research to 
determine which patients may have a survival benefit with the addition of lapatinib to 
chemotherapy treatments.  The TTP was increased in this study which implies that lapatinib and 
capecitabine are clinically beneficial to women who have failed trastuzumab therapy.  This study 
also showed no increase in cardiac toxicity in the treatment arm. 
Kaufman, Stein, Casey and Newstat (2008) suggest although breast cancer is currently 
incurable, by utilizing the new treatment therapies and strategies, it may allow breast cancer to 
be managed as a chronic disease.  The research demonstrated a longer TTP then the capecitabine 
monotherapy.  This study also analyzed the benefit of lapatinib and capecitabine in treating brain 
metastasis since both drugs cross the blood-brain barrier.  Trastuzumab, however, does not.  
Lapatinib plus capecitabine fills a void after the patient had disease progression while on 
trastuzumab.   
Mantel-Haenszel Meta-Analysis Method 
Meta-analysis, the methodologies of synthesizing existing evidence to answer a clinical or 
other research question, is a dynamic area of research.  The furor of methodological activity 
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reflects the clinical importance of meta-analysis and its potential to provide conclusive answers, 
rather than incremental knowledge contributions.  When the original data is unavailable, 
researchers have to combine the evidence in a two stage process, retrieving the relevant summary 
effects statistics from publications and using a suitable meta-analysis model to calculate an 
overall effect estimate.  
The Mantel-Haenszel (MH) meta-analysis method which can be used to calculate odds ratio 
(OR), risk ratio (RR), and risk difference (RD) (Mantel & Haenszel, 1959).  The MH method is 
based on either a fixed effect or random effect model, where the weight is assigned to each study 
based on that study alone.  Under the fixed effect model, there is an assumption that only one 
true effect exists which underlies all the studies in the meta-analysis.  However, the random 
effects model incorporates an assumption that the different studies are estimating different, yet 
related, intervention effects.  In both models, the observed effect size in a study is assumed to 
estimate the corresponding population effect with random error that stems only from the chance 
factor associated with subject level sampling error in that study from the population of potential 
subjects.  When comparing randomized control trials the goal is to detect incidence of a single 
health outcome between different study groups (Borenstein, Hedges, Higgins, & Rothstein, 
2009). 
Heterogeneity  
 
Heterogeneity refers to the various responses to a given treatment among included studies.  It 
can relate to the biological differences among individuals, but also to other differences that are 
not as easily detectable (Leandro, 2008).  Heterogeneity has two sources of variability that 
explain the differences in a set of studies utilized in a meta-analysis.  One source of variability is 
due to sampling error.  Sampling error variability is always present in a meta-analysis, because 
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every study uses different study patients and no two patients are identical.  The other source of 
heterogeneity is the between-study variability, which can appear in a meta-analysis when there is 
true heterogeneity among population effect size estimated by the individual studies.  The 
between-studies variability is due to the influence of an indeterminate number of characteristics 
that vary among the studies. 
Publication Bias 
The one type of publication bias that occur in meta-analysis is sampling bias where only 
studies showing significant difference are published, this implies that some complete studies are 
not published and the results resides in the investigator’s "file drawer" a term coined by 
psychologist Robert Rosenthal in 1979.  Non -publication is not a direct result of a rejected 
manuscript, but a failure of the investigator to write up and submit the trial results (Rosenthal, 
1979).  Since published studies are easier to identify and retrieve than unpublished studies, or 
studies that resulted in negative or null findings; the studies used in a meta-analysis may over-
represent published work and exaggerate statistical significance   
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Chapter III: STUDY DESIGN AND METHODS 
The studies enrolled randomized patients to receive lapatinib plus capecitabine or 
capecitabine monotherapy within strata defined according to disease stage and the presence or 
absence of visceral disease (metastatic disease) to other organs such as: bones, liver, lung, and/or 
brain.  The eligibility criteria for enrollment was documented HER2 positive status by 
immunohistochemistry or gene amplification by fluorescence in situ hybridization, locally 
advanced or metastatic breast cancer, and minimum prior treatment(s) that included an 
anthracycline, a taxane, and trastuzumab.  
Trial Identification 
I performed a computerized search of MEDLINE database (last search, October 26, 2014), 
online proceedings of the San Antonio Breast Cancer Symposium (years 2008-2014; last 
searched October 26, 2014), and the online proceeding of the American Society of Clinical 
Oncology (ASCO) Annual Meeting (years 2005-2014; last search October 26, 2014), using the 
combinations of the following keywords: “breast cancer”, “lapatinib”, “capecitabine”, “HER2”, 
“neoplasm” and “chemotherapy.”  I reviewed the reference list of every published clinical article 
used in the meta-analysis to find any missing relevant studies. 
The extractor used the trial eligibility schema (figure 1) to determine which clinical trials met 
the research conditions.  The following information was recorded about each eligible clinical 
trial used in the meta-analysis: first author, journal name and year of publication, number of 
patients assign to each treatment arm, the number of outcome events recorded, and the dosing 
schedule for both treatment arms. 
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Figure 1 
Trial identification schema 
 
 
 
Potentially relevant published 
articles identified (n= 86) 
Clinical trials screened on basis 
of title or abstract (n= 23) 
Exclude because non randomized 
controlled trials (n= 17) 
 Single treatment arm 
Randomized controlled trials 
reviewed in detail (n= 6) 
Randomized, controlled trials 
excluded (n= 3) 
 Duplicate reports of 
previous trials 
 Novel capecitabine dosing 
 
Eligible randomized clinical 
trials (n=3) 
Reports of nonclinical trials 
excluded (n= 63) 
 Review papers 
 Not studies on humans 
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Study Treatment Protocol 
Patients in the treatment arm received lapatinib dosed at 1,500 mg per day continuously plus 
capecitabine 2,000 mg per square meter of body surface area on days 1 through 14 of a 21 day 
cycle.  Patients in the control arm received capecitabine at a dose of 2,500 mg per square meter 
of body surface area on days 1 through 14 of a 21 day cycle.  Baseline characteristics of the 
women enrolled in the clinical trials is listed in table 1.  
Table 1 
Baseline Characteristics of Women Included in the Analysis 
 Lapatinib + Capecitabine Capecitabine 
 Cameron      Geyer   Kaufman  Cameron      Geyer   Kaufman 
Gender 
(female/male) 
207 / 0 206 / 0 163 / 0 201 / 0 193 / 0 161 / 0 
Cancer Stage       
IIIB / IIIC 8 7  8 4  
IV 199 156 
96 % 
metastatistic 
193 154 
96 % 
metastatistic 
Median TTP 18.8 months 8.4 months 6.2 months 16.2 months 4.4 months 4.3 months 
Observation 
Duration 
180 – 220 
weeks 
70 – 80 weeks 80 – 90 weeks 
180 – 220 
weeks 
70 – 80 weeks 80 – 90 weeks 
 
The study patients were all female for the clinical trials.  The Cameron and Geyer studies 
reflect a balanced participant number of stage III patients in each arm, but in the Kaufman study 
reports 96 percent of the participants had stage IV cancer with no additional information 
provided.  Stage IIIB or IIIC locally advanced breast cancer means that the patient does not have 
a tumor is distant organ such as: bone, brain, liver, or lung.  Stage IV is commonly defined as 
metastatic breast cancer and it has all the characteristics of Stage III with the inclusion of a tumor 
found in one or more of the distant organs listed above. 
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Median time to tumor progression (TTP) reflects the length of time from start of treatment 
until 50 percent of the women experience death or disease progression the termination criteria for 
treatment.  Study observation duration is estimated based on the Kaplan-Meier curve.  The 
baseline characteristics were used to check the data integrity, since the numbers reported in the 
journal articles are very similar.  The additional information provided by table 1 provides enough 
evidence that the clinical trials are unique and data reported is accurate 
Mantel-Haenszel Method 
 
When the studies have a dichotomous (binary) data the results of each study can be presented 
in a 2×2 table (Table 2) giving the number of participants who experience the event or do not 
experience the event (non-event) in each of the two study groups treatment or control.   
Table 2 
 
Mantel-Haenszel Data Layout 
 
Study Event 
Non-
Event 
Total 
Treated 
Treatment Ai Bi N1i 
Control Ci Di N2i 
  
The Mantel-Haenszel (MH) odds ratio is an alternative way of comparing how likely events 
are between two groups.  The odds ratio is simply the odds of the event occurring in one group 
divided by the odds of the event occurring in the other group.  I will use ORi to denote the odds 
ratio (effect size) for each ith study.   
MH Raw Odds Ratio Formula   
    
( / )
( / )
i i
i
i i
A B
OR
C D

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Re-arrange above formula to this. 
*
*
i i
i
i i
A D
OR
B C

 
 
MH Variance Formula  
*
i
i
i i
n
V
B C

   , where i i i i in A B C D     
The weighted mean ORMH is the sum of the products (effect size ORi times weight Wi) 
divided by the sum of the weights.  The study weights are assigned with the goal of minimizing 
the with-in study error; meaning that larger studies, which have smaller standard errors, are given 
more weight than smaller studies, which have larger standard errors.   
MH Weight Equation  
1
i
i
W
V

  
 
MH Pooled Summary Odds Ratio Equation 
 
1
1
( )
k
i i
i
MH k
i
i
W OR
OR
W





 
 
To determine the strength of this relationship, we can estimate the raw odds ratio across 
the 2 x 2 table.  Although, the raw odds ratio indicates how much or worse, on average, the 
treatment group performed relative to the control group, its scale is asymmetric with a lower 
bound of zero and an upper bound of infinity figure 2 (Petscher & Schatschneider, 2013).  Thus, 
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the comparison of the OR from each clinical trial is not feasible since they can have different 
scales. 
 
Figure 2 
Distribution of Raw Odds Ratio 
Therefore, what is typically done with raw odds ratio is transformed to a scale symmetric 
about zero by taking the natural logarithm.  The log transformation makes the scale symmetric: 
the log of 0 is minus infinity, the log of 1 is zero, and the log of infinity is infinity.  This 
transformation yields the log odds ratio in which a value of one indicates no intervention effect 
figure 3 (Petscher & Schatschneider, 2013).  Once, the log transformation is done the log OR can 
be compared and conclusions concerning the magnitude of the intervention effect can be 
analyzed.  Graphical displays for meta-analysis performed on ratio scales usually use the log 
scales as well.  This has the effect of making the confidence intervals appear symmetric, for the 
same reason (Higgins & Green, 2011). 
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Figure 3 
Distribution of Log Odds Ratio 
The odds ratio is transformed from raw units to log units to compute the Z-score and 
confidence limits. The ln (ORMH) is computed by taking the natural log (ln) of ORMH. 
ln ln( )MH MHOR OR  
The MH approach required the following computed frequency values for each study to be 
calculated, which will be summed across all studies, and then used to compute the variance of 
the summary effect.  For each study (i) calculate the following values (the variable name is not 
significant): 
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MH Pooled Standard Error Estimate  
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MH 95 percent Confidence Interval for the Summary Effect, in log units:  
 
 
ln
ln
ln( ) 1.96*
ln( ) 1.96*
MH
MH
MH OR
MH OR
LowerLimit OR SE
UpperLimit OR SE
 
   
 
MH Z Value 
The calculation of the Z-value and the one-tailed test for the p-value are as follows where Φ 
(Z) is the standard normal cumulative distribution.  
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Heterogeneity 
 
In meta-analysis, the usual way of assessing whether a set of single studies is homogeneous 
is by means of the Q statistic; however, the Q statistic only informs meta-analysts about the 
presence versus the absence of heterogeneity, but it does not report on the extent of such 
heterogeneity.  The I2 index is used to report the extent of heterogeneity.  The principal 
advantage of I2 index is that it can be calculated and compared across meta-analyses of different 
sizes, of different types of study, and using different types of outcome data (Higgins & 
Thompson, 2002). 
Q Statistic 
The Q statistic is useful in detecting the with-in study variation.  The Q statistic has a chi-
squared distribution with k-1 degrees of freedom where k is the number of studies utilized in the 
meta-analysis (Lipsey & Wilson, 2001).  The Q statistic is testing the null hypothesis in that the 
studies are homogeneous in the combined analysis or H0: Q = 0 implying the studies is 
evaluating the same effect versus the alternative hypothesis, HA: Q  0 implying the studies is 
not evaluating the same effect in the combined analysis.   
The formula for the Q statistic: 
( )
i i MH
Q Ln Lnw OR OR    
 
The Q statistic can produce inaccurate results in extreme situations.  When there is only a 
few studies the Q statistic can give a false assumption of homogeneity.  On the other hand, when 

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there are a large number of studies, the Q test has high power to detect even a small amount of 
heterogeneity that may be clinically unimportant.  When the meta-analysis incorporates only a 
few studies, utilizing the random effect model is appropriate when there are concerns about 
homogeneity.  The random-effects method incorporates an assumption that the different studies 
are estimating different, yet related, intervention effects.  The random-effects method and the 
fixed-effect method will give identical results when there is no heterogeneity among the studies. 
I2 Index 
The I2 index is also used in detecting heterogeneity between studies which can be interpreted 
as the percentage of variability in effect estimates that are due to heterogeneity rather than 
chance or sampling error.  Between-study heterogeneity is estimated using the I2 statistic; 
typically, values greater the 50 percent are considered large, 25 percent to 50 percent modest, 
and less than 25 percent low heterogeneity (Higgins & Green, 2011).  The formula for the I2 
index: 
2
*100%
Q df
QI
 
  
 
 
 
In meta-analyses that include between 2 to 4 studies such a sample is not usually adequate to 
accurately estimate heterogeneity, leading to a false homogeneity assumption (Kontopantelis, 
Springate, & Reeves, 2013).  These estimates can have large uncertainty, especially in the 
presence of few trials, and should be interpreted with caution. 
Publication Bias 
 
Publication bias is assessed using a funnel and forest plots.  A funnel plot is a scatter plot of 
the effect estimates from individual studies against the measure of each study’s precision.  A 
forest plot is a graphical representation of meta-analysis data.   
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In a funnel plot the y axis is the standard error of the effect estimate and the natural log of the 
odd ratio is the x axis.  The diagonal lines indicate the triangular region within which 95 percent 
of studies are expected to lie in the absence of both biases and heterogeneity (Sterne et. al., 
2011).  The solid vertical line is the line of no intervention effect.  A funnel plot places effect 
estimate for larger, more powerful studies are towards the top of the plot and estimates from 
smaller, less powerful studies should scatter more widely at the bottom. 
In the absence of publication bias we would expect the studies to be distributed 
symmetrically about the combined effect size which is observed in the funnel plot.  In the 
absence of bias and between study heterogeneity, the scatter will be due to sampling variation 
alone and the plot will resemble a symmetrical inverted funnel.  If no bias is present then the 
fixed effect assumption that the true treatment effect is the same in each study is valid.   
By contrast, in the presence of bias, we would expect that the bottom of the plot would show 
a higher concentration of studies on one side of the mean than the other.  This would reflect the 
fact that smaller studies (which appear toward the bottom) are more likely to be published if they 
have larger than average effects, which makes them more likely to meet the criteria for statistical 
significance (Borenstein et al., 2009).   
When assessing forest plots one should compare the point estimate for each study to all other 
studies included in the meta-analysis, and to the combined point estimate to assess publication 
bias.  The point estimates should not be scattered across the graph, for example, if one point 
estimate favors the control and the other point estimate favors the treatment that could indicate 
that publication bias may be present in a meta-analysis.  The assessment of a forest plot should 
be to evaluate the graph holistically.  The graph portion should have the point estimate for each 
study that is grouped close together near the summary effect estimate.  The point estimates 
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should not be scattered across the graph, for example if one point estimate favors the control and 
the others point estimates favor of the treatment that is an indication that bias may be present in 
the meta-analysis.  The 95 percent CI should overlap similar portions and also overlap the 
summary effect estimate. 
The forest plot provides the summary data entered for each study. In addition, it provides the 
weight for each study; the effect measure, method and the model used to perform the meta-
analysis;  the confidence intervals used; the effect estimate from each study, the overall effect 
estimate, and the statistical significance of the analysis.  In a forest plot the vertical line which 
corresponds to the value one is the line of no intervention effect.  If one is included in the 95 
percent confidence intervals, it indicates that there is no statistical significant difference between 
the treatment and control at five percent significance level.  If one is not included in the 95 
percent confidence intervals, it indicated that there are statistically significant difference between 
the treatment and control at five percent significance level.  This is applicable for effect estimates 
for the individual study level and for the overall estimate for the meta-analysis. 
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Chapter IV:  RESULTS 
 
The results of the systematic review resulted in only three eligible trials that met the defined 
search parameters.  The key elements for the clinical trials are that patients had disease 
progression while on or after treatment that included an anthracycline, a taxane, and trastuzumab.  
Analysis was conducted using Comprehensive Meta-Analysis software (Version 3.3.070, 
Biostat, Englewood, NJ). 
The studies randomized patients 1:1 to lapatinib plus capecitabine or capecitabine. The 
eligible trials identified 1,131 patients with HER2 positive breast cancer, 576 assigned to 
lapatinib plus capecitabine (LC) and 555 assigned to capecitabine (C).  The data extracted from 
the clinical trials is detailed in table 3. 
Table 3 
Lapatinib plus Capecitabine versus Capecitabine Data Table 
 
           Lapatinib + Capecitabine                  Capecitabine 
Study 
 
Event Non- 
Event 
    Total 
 
         
Event 
Non-
Event 
Total Study     
Total 
  Cameron 16
8 
39 207 1
72 
29 201 408 
Geyer 12
1 
85 206 1
26 
67 193 399 
   
Kaufman 
92 71 163 1
04 
57 161 324 
 
I used the number of events per arm to calculate odds ratio (OR) and their 95 percent 
confidence interval (CI).  An event is defined as patient death , the spread of cancer to new 
locations within the body, or increased growth of a cancerous lesion.  The combined ORs to 
calculate pooled point estimates with the corresponding CIs using the Mantel-Haenszel fixed 
effect method.  I tested heterogeneity using the Q statistic and I2 index.  Publication bias is 
assessed using funnel and forest plots. 
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Mantel-Haenszel Odds Ratio 
The summary the odds ratio is shown in Figure 4.  Each study is shown by the point estimate 
of the odds ratio, lower and upper limits of the 95 percent confidence interval, p-value and forest 
plot.  The forest plot the square black box indicates the relative weight assigned to each study 
and the 95 percent confidence interval is shown by the extending whiskers.  The combined odds 
ratio estimate and the 95 percent confidence interval by MH fixed effect calculations are shown 
by the diamond at the bottom.  The diamond is centered at the combined point estimate and the 
width of the diamond reflects the 95 percent confidence interval.   
Figure 4 
 
Mantel-Haenszel Odds Ratio 
 
The analysis of the odds ratio shows that the Cameron study has a point estimate of 0.726, 95 
percent CI of 0.429 to 1.228 and a p value of 0.233.  Based on this result the Cameron study does 
not show a decrease in tumor progression because the 95 percent confidence interval of the study 
overlaps one the line of no intervention effect. So, there is no statistical significance at the study 
level.  
The analysis of the odds ratio shows that the Geyer has a point estimate of 0.757, 95 percent 
CI of 0.504 to 1.136 and a p value of 0.179.  Based on this result the Geyer study does not show 
Model Study name Statistics for each study MH odds ratio and 95% CI
MH Lower Upper 
odds ratio limit limit p-Value
Cameron 0.726 0.429 1.228 0.233
Geyer 0.757 0.504 1.136 0.179
Kaufman 0.710 0.454 1.111 0.134
Fixed 0.733 0.565 0.952 0.020
0.5 1 2
Lapatinib + Capecitabine Capecitabine
Mantel - Haenszel Odds Ratio
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a decrease in tumor progression because the 95 percent confidence interval of the study overlaps 
one the line of no intervention effect. So, there is no statistical significance at the study level.  
The analysis of the odds ratio shows that the Kaufman has a point estimate of 0.710, 95 
percent CI of 0.454 to 1.111 and a p value of 0.134.  Based on this result the Kaufman study does 
not show an a decrease in tumor progression because the 95 percent confidence interval of the 
study overlaps one the line of no intervention effect. So, there is no statistical significance at the 
study level.  
The analysis of the odds ratio shows the combined meta-analysis has a point estimate of 
0.733, 95 percent CI of .565 to .952 and a p value of 0.020.  Based on this result the combined 
meta-analysis the 95 percent confidence interval combined effect estimate does not overlap one 
the line of no intervention effect.  There is statistical significance at the meta-analysis level.  The 
odds ratio point estimate of 0.733 represents an overall 26.7 percent a decrease in women 
experiencing tumor related events in the lapatinib plus capecitabine arm versus the capecitabine 
monotherapy.  Even though the benefit is moderate it shows that there is statistical support to 
pursue new clinical trials utilizing lapatinib plus capecitabine as a new treatment option for 
women with metastatic breast cancer.   
Heterogeneity  
The test for heterogeneity utilizing the Q statistic and I2 index are recorded in the figure 5.   
 
 
Figure 5 
 
Q statistic and I2 index 
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The fixed and random effect models produce the same point estimate, Z-value, and p value 
meaning there is no heterogeneity among the studies.  The fixed effect model is more 
conservative than the random effect model so I am reporting the results for the fized effect 
model. 
The I2 index is the percentage of variability in effect estimates that are due to heterogeneity 
rather than chance or sampling error.  The I2 index has a value of 0.000 which suggest that there 
is low heterogeneity in this meta-analysis.  Since, this meta-analysis includes only three clinical 
studies the sample size may not be adequate to accurately estimate heterogeneity resulting in an 
incorrect zero of the I2 index.  Potentially leading to a false homogeneity assumption and should 
be interpreted with caution.  In general, meta-analyses which include between two to four studies 
are not usually adequate to accurately estimate heterogeneity, leading to a false homogeneity 
assumption (Kontopantelis, Springate, & Reeves, 2013).  These estimates may have a large 
uncertainty due to the lack of published clinical trials available for examination and should be 
interpreted with caution. 
Publication Bias 
Publication bias is assessed with a funnel plot and a forest plot.  The table 4 is the natural log 
(ln) of the odds ratio for each of the included studies.   
Table 4 
Natural Log of Mantel-Haenszel Odds Ratio 
Study Name MH Odds Ratio ln (MH odds ratio) 
Cameron 0.726 -0.320 
Geyer 0.757 -0.278 
Kaufman 0.710 -0.342 
Combined 0.733 -0.311 
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In a funnel plot the standard error of the effect estimate is the y axis and the natural log of the 
odd ratio is the x axis.  The vertical line represents the natural log of the combined estimate of 
0.733 which has a value of -0.311.  Comprehensive Meta-Analysis software uses the term log to 
represent the natural log.  All the studies are represented by the open circles in figure 6.  
 
Figure 6 
 
Funnel Plot of Standard Error by Log Odds Ratio 
 
Starting from the top of the graph the first circle corresponds to the Geyer study, the second 
circle corresponds to the Kaufman study and the final circle corresponds to Cameron study.  The 
relative weight of each study is indicated by their location on the funnel plot.  The Geyer study 
has largest relative weight, since it is located at the top of the graph.  The Kaufman study has the 
second largest relative weight, since it is located between the Geyer and Cameron studies.  The 
Cameron study has the smallest relative weight comapared to Geyer and Kaufman.  All the 
studies are close to the fixed estimate and closely grouped together which indicates the meta-
analysis is not expressing publication bias.  In the absence of publication bias we would expect 
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the studies to be distributed symmetrically about the combined effect estimate which is observed 
in the above funnel plot.   
The second method of detecting publication bias is by a forest plot.  The forest plot figure 7 
includes the study name, MH odds ratio estimate, the lower and upper limits of the 95 percent 
CI, the p value, a line graph of the point estimate with extending whiskers representing 95 
percent CI, and the relative weight assigned to each study. 
 
 
 
Figure 7 
 
Forest Plot and Relative Weight Analysis 
 
The first assessment of the forest plot is to assess the plot holistically.  The graph portion 
shows that each study point estimate (vertical line) is either slightly above or below the 
combined point estimate.  The 95 percent CI cover the same portion of the graph for each study 
as well as the summary effect estimate.  All the study point estimates favor the treatment 
intervention of lapatinib plus capecitabine.  Based on the funnel and forest plots this meta-
analysis is not representing publication bias. 
In assessing the relative weights of studies, a large study provides a good estimate of the 
common effect and is assigned a larger weight; a small study offers a less reliable estimate of 
that same effect, so it is assigned a smaller weight.  The Cameron study point estimate is 0.726 
with a relative weight of 24.88 percent; the Kaufman study point estimate is 0.710 with a relative 
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weight of 34.49 percent; the Geyer study point estimate in 0.757 with a relative weight of 40.62 
percent.  Under the fixed effect model these studies are all estimating the same effect with the 
Geyer study providing a more precise estimate of the effect.  Consequently, the Geyer study is 
assigned 40.62 percent of the weight in the combined point estimate with the remaining 59.38 
percent divided amongst the remaining studies.  Since, the Geyer study is assigned a 
disproportionate amount of weight it is evident that the Geyer study is more significant, 
statistically, than the Kaufman and Cameron studies.  The disproportionate weight given to the 
Geyer study has caused the combined point estimate to definitively shift in favor of the Geyer 
point estimate.    
The study by Geyer has a point estimate of 0.757, a 95 percent CI of 0.504 to 1.136, a p 
value of 0.179, and a relative weight of 40.62 percent.  Based on the above forest plot the Geyer 
study the 95 percent CI includes the value one which indicates there is no treatment difference 
between lapatinib and capecitabine versus capecitabine monotherapy.  As a result, there is no 
statistical significance at the study level.  The Geyer study has the smallest variance therefore the 
study has more relative weight than Cameron and Kaufman studies.   
The study by Kaufman has a point estimate of 0.710, a 95 percent CI of 0.454 to 1.111, a p 
value of 0.134, and a relative weight of 34.49 percent.  Based on the above forest plot the 
Kaufman study shows 95 percent CI includes the value one which indicates there is no treatment 
difference between lapatinib and capecitabine versus capecitabine monotherapy.  As a result, 
there is no statistical significance at the study level.  The Kaufman study has a slightly larger 
variance when compared to Geyer therefore the study has more relative weight than the Cameron 
study. 
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The study by Cameron has a point estimate of 0.726, a 95 percent CI of 0.429 to 1.228, a p 
value of 0.233, and a relative weight of 24.88 percent.  Based on the above forest plot the 
Cameron study shows 95 percent CI includes the value one which indicates there is no treatment 
difference between lapatinib and capecitabine versus capecitabine monotherapy.  As a result, 
there is no statistical significance at the study level.  The Cameron study has the largest variance 
therefore the study has the least relative weight when compared to Geyer and Kaufman.   
The combined meta-analysis result has a point estimate of 0.733, a 95 percent CI of .565 to 
.952, and a p value of 0.020.  Based on the above forest plot the combined fixed point estimate, 
the 95 percent confidence interval (indicated by the left and right edges of the diamond) of the 
combined point estimate does not overlap value one which indicates there is a statistically 
significant treatment difference between lapatinib and capecitabine versus capecitabine 
monotherapy at five percent significance level.  So, there is statistical significance at the meta-
analysis level.  New hypotheses can be evaluated in phase II or III clinical trials utilizing 
lapatinib plus capecitabine in the treatment of metastatic breast cancer. 
Utilizing lapatinib plus capecitabine as first line therapy will provide a more accurate 
estimate of the survival benefit to women diagnosed with metastatic breast cancer then provided 
in this meta-analysis.  The odds of an event occurring in the combination therapy group was 
reduced by 26.7 percent when compared to the monotherapy group.  There is currently a clinical 
trial NCT00496366 Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line 
Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer 
sponsored by Rutgers, The State University of New Jersey.  The clinical study is ongoing and 
expected to be concluded in September of 2016 with survival and time to progression data.   
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The use of lapatinib plus capecitabine should also be considered for women who are older or 
have compromised cardiac function at time of initial diagnosis.  Older women are at a 20 percent 
increased risk of developing congestive heart failure after finishing chemotherapy.  The clinical 
trial NCT01262469 Phase II Study Evaluating the Toxicity and Activity of the Combination 
Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over with Metastatic Breast Cancer 
over Expressing HER2 sponsored by UNICANCER has concluded, but the clinical results of this 
trial have not been published.  This clinical study will give a more precise cardiac toxicity profile 
and survival benefit of lapatinib plus capecitabine in older patients. 
The clinical trials mentioned above offer a new option for newly diagnosed HER 2 positive 
breast cancer patients.  Current research is investigating the role of lapatinib in combination with 
other chemotherapy agents and in adjuvant therapy for early breast cancer progression or relapse.  
The common benefit for lapatinib plus capecitabine is the convenience of oral administration.  
No longer, will women have to take time out of their schedules for their weekly or monthly 
chemotherapy infusions thus improving quality of life.   
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Chapter V: CONCLUSION 
 
The primary limitation of this meta-analysis is the small number of clinical trials used when 
interpreting the results.  First, my approach was based on data abstracted from publications and 
not individual patient data; thus, results should be viewed as hypothesis generating, and not as 
definitive evidence.  Second, using short term results from only three randomized trials may be a 
source of bias when calculating the combined point estimate.  Additional limitations are the 
sources of heterogeneity not taken into account due to the limited number of available studies, 
such as: clinical differences among the patient populations, patient baseline disease severity or 
characteristics, study design, or other sources that are not easily detected.   
The goal of chemotherapy or treatment is to maximize quality of life, prolong life, stabilize 
the disease, and manage or reduce symptoms.  Lapatinib plus capecitabine indicated the event 
occurred 26.7 percent less frequently for women treated with combination lapatinib plus 
capecitabine in comparison to women treated with capecitabine monotherapy.  Although the 
decreased odds of tumor advancement is moderate, it is significant when life expectancy is 
measured in weeks and not years. 
The ultimate cure for breast cancer remains elusive, but there is still hope for a cure with our 
advancements in medical science, for instance earlier detection and targeted chemotherapy 
drugs.  Also our enhanced understanding of genetics, such as testing for breast cancer 
susceptibility protein (BRCA) genes and other abnormal genes responsible for cancer 
development.  The disease is so complex, diverse, and so subtly connected to genetics and 
environmental factors, such as hormone therapy after menopause and oral contraceptives, that 
finding a cure can often feel impossible.  While a cure has not yet been found, public perception 
surrounding breast cancer has changed dramatically in the past few decades.  Once a disease that 
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woman felt ashamed to discuss, breast cancer now has lost much of its stigma.  The combined 
efforts of Susan G. Komen for the Cure ©, the Breast Health Global Initiative, the U.S. Centers 
for Disease Control and Prevention, and advances in medical science has greatly improved 
access to treatment and screening.  Greater awareness has been brought to this disease and with 
increased funding for research and drug development we have seen an increased success rate in 
breast cancer treatment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
REFERENCES 
References marked with an asterisk indicate studies included in the meta-analysis 
Ben Venue Laboratories Inc. (2006) Adriamycin [package insert]. Bedford, OH, Ben Venue 
Laboratories Inc. 
Borenstein, M., Hedges, L. V., Higgins, J.P.T., Rothstein, H. R. (2011).  Introduction to Meta-
Analysis.  West Sussex, United Kingdom: John Wiley & Sons Ltd. 
Bowles, E. J., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., . . .  
Pharmacovigilance Study Team. (2012) Risk of heart failure in breast cancer patients after 
anthracycline and trastuzumab treatment: a retrospective cohort study.  Journal of the National 
Cancer Institute, 104(17):1293-305. 
Cameron, D., Casey, M. Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., . . .  Geyer. C. E.  
(2008)  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine 
alone in women with advanced breast cancer that has progressed on trastuzumab: Update 
efficacy and biomarker analyses. Breast Cancer Research and Treatment, 112, 533-543. 
*Cameron, D., Casey, M., Olivia, C., Newstat, B., Imwalle, B., Geyer, C. E. (2010) Lapatinib plus 
capecitabine in women with HER-2-postive advanced breast cancer: Final survival analysis of a 
phase III randomized trial. The Oncologist, 15, 924-934.  
Donegan, W. L., & Spratt, J. S. (2002) Cancer of the breast (5th ed.), History of breast cancer (pp. 1-
14).  St. Louis, MO: Saunders/Elsevier.  
*Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., … Cameron, D. 
(2006).  Lapatinib plus capecitabine for HER2- positive advanced breast cancer.  New England 
Journal of Medicine, 355, 2733-2743.  
43 
 
GlaxoSmithKiline LLC. (2015). Tykerb® or Tyverb®  [package insert]. Research Triangle Park, NC: 
GlaxoSmithKline LLC. 
Higgins, J. P. T., & Green, S. (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.   
Retrieved July 29, 2015, from www.cochrane-handbook.org. 
http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.html 
Higgins, J.P., & Thompson, S.G. (2002) Quantifying heterogeneity in a meta-analysis. Statistics in 
Medicine, 21:1539-1558. 
Hudis, C. A. (2007) Trastuzumab - Mechanism of Action and Use in Clinical Practice. New England 
Journal of Medicine, 357:39-51.  
Jemal, A., Siegel, R., Xu, J., Ward, E. (2010) Cancer Statistics, 2010. CA: A Cancer Journal for 
Clinicians, 60, 277-300.  
*Kaufman, B., Stein, S., Casey, M. A., Newstat, B. O., (2008).  Lapatinib in combination with 
capecitabine in the management of ErbB2-positive (HER2- positive) advanced breast cancer.  
Biologics: Targets & Therapy, 2, 61-65.  
Kontopantelis E, Springate DA, Reeves D (2013) A Re-Analysis of the Cochrane Library Data: The 
Dangers of Unobserved Heterogeneity in Meta-Analyses. PLoS ONE 8(7): e69930. 
doi:10.1371/journal.pone.0069930 
Kopper, L. (2008) Lapatinib: A sword with two edges. Pathology and Oncology Research, 
14, 1-8.  
Leandro, G. (2008) Meta-analysis in medical research: the handbook for the understanding and 
practice of meta-analysis.  Malden, MA: Blackwell Publishing Ltd. 
Lipsey, M., Wilson, D. B. (2001) Practical meta-analysis.  Thousand Oaks, CA: Sage Publications, 
Inc. 
44 
 
Mantel, N., & Haenszel, W.,  (1959). Statistical aspects of the analysis of data from retrospective 
studies of disease.  Journal of the National Cancer Institute, 22, 719-748. 
Pinder, M., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H. (2007) Congestive heart 
failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.   
Journal of Clinical Oncology, 25, 3808-3815. 
Petschner, Y. M., Schatschneider, C., (2013) Applied Quantitative Analysis in Education and the 
Social Sciences. New York, NY: Routledge Publication, Inc. 
Random History. (2008). History of Breast Cancer. Retrieved March 29, 2011, from 
http://www.randomhistory.com/1-50/029cancer.html 
Rosenthal, R. (1979) File drawer problem and tolerance for null results. Psychological  Bulletin, 
86:638-41. 
Ryan, Q., Ibrahim, A., Cohen, M. H., Johnson, J., Ko, C.W., Sridhara, R. … Pazdur, R.    (2008) 
FDA Drug Approval Summary: Lapatinib in combination with capecitabine for previously 
treated metastatic breast cancer that overexpress HER-2. The Oncologist, 13, 1114-1119.  
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., … Norton, L. 
(2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast 
cancer that overexpress HER2.  New England Journal of Medicine, 344, 782-792.  
Sterne, J.A.C., Sutton, A.J., Ioannidis, J.P.A., Terrin, N., Jones, D.R., Lau, J., … Higgins, J.P.T 
(2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analysis 
of randomized controlled trials.  British Medical Journal, 343, d4002. 
Tevaarwerk, A. J., & Kolesar, J. M. (2009) Lapatinib: A small molecule inhibitor of epidermal   
growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in 
the treatment of breast cancer.  Clinical Therapeutics, 31, 2332-2348.  
45 
 
Walko, C. M., & Lindley, C. (2005) Capecitabine: A review.  Clinical Therapeutic, 27, 23-43.  
World Health Organization (2015) GLOBOCAN 2012: Estimate Cancer Incidence, Mortality and 
Prevalence Worldwide in 2012. Retrieved April 5, 2015, from 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
APPENDIX 
 
Data Table of the Seven Potentially Eligible Clinical Studies 
 
Author Lapatinib + 
Capecitabine dosing 
schedule 
Capecitabine dosing 
schedule 
Included in Meta-
analysis 
Cameron Lapatinib 1,250 mg/day of a 
21 day cycle 
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
Yes, final report for 
clinical trial 
EGF100151 
  Capecitabine 2,000 mg/m2 
days 1-14 of a 21 day cycle 
    
Cameron Lapatinib 1,250 mg/day of a 
21 day cycle 
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
No, interim analysis for 
clinical trial 
EGF100151  
  Capecitabine 2,000 mg/m2 
days 1-14 of a 21 day cycle 
    
Gajria Lapatinib 1,250 mg/day of a 
21 day cycle  
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
No, treatment arm novel 
capecitabine dosing 
schedule 7 days on 7 
days off  
  Capecitabine 2,000 mg/m2 
days 1-7 and 15-21. No 
capecitabine day 8-14 of a 
21 day cycle 
    
Geyer Lapatinib 1,250 mg/day of a 
21 day cycle 
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
Yes, final report for 
clinical trial 
NCT00078572 
  Capecitabine 2,000 mg/m2 
days 1-14 of a 21 day cycle 
    
Kaufman Lapatinib 1,250 mg/day of a 
21 day cycle 
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
Yes, no clinical trial 
identified 
  Capecitabine 2,000 mg/m2 
days 1-14 of a 21 day cycle 
    
Ryan Lapatinib 1,250 mg/day of a 
21 day cycle 
Capecitabine 2,500 mg/m2 
on days 1-14 of a 21 day 
cycle 
No, duplicate 
publication of clinical 
trial NCT00078572 
  Capecitabine 2,000 mg/m2 
days 1-14 of a 21 day cycle 
    
 
 
 
